Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITAALD
NCT07060638Phase 2Recruiting
- Start
- Jan 2026
- Primary completion
- Dec 2029
- Modality
- Cytokines & Interferons, Small Molecules, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of eflepedocokin alfa, acamprosate in alcoholic hepatitis (AH), alcohol use disorder (AUD). Started Jan 2026; status: recruiting.
02
Drugs
eflepedocokin alfaacamprosate
03
Conditions
alcoholic hepatitis (AH)alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT07060638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07060638.